Feb 26 (Reuters) - Novavax raised its adjusted revenue forecast for 2026 on Thursday, banking on milestone payments from ...
Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 24.4% in the morning session after the company reported fourth-quarter financial results that significantly beat analyst ...
Novavax (NasdaqGS:NVAX) reported a surprise profit for the fourth quarter, alongside revenue that was above prior expectations. The company is shifting its business model by transferring ...
Novavax’s alliance with Sanofi came at an opportune time for the beleaguered vaccine developer. Its protein-based Covid-19 vaccine never reached the revenue highs achieved by the messenger RNA ...
Aug 6 (Reuters) - Novavax (NVAX.O), opens new tab raised its full-year adjusted revenue forecast on Wednesday, betting on the strength of vaccine supply partnerships, including with Serum Institute of ...
Under the non-exclusive agreement, Pfizer will utilize Novavax’s Matrix-M adjuvant in products across two disease areas, with Novavax receiving a $30 million upfront payment. Additionally, the ...
GAITHERSBURG, Md., Oct. 22, 2025 /PRNewswire/ -- Novavax, Inc. today announced that it has further executed against its planned transformation into a lean, agile operating model by signing definitive ...
After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter from the agency, but only for people 65 and older and those 12 and up who ...
Hosted on MSN
Novavax Stock Suffers Sharpest Drop In Months After $225M Debt Deal; Retail Still Leans Bullish
Novavax slid Thursday in its worst session in more than four months after laying out plans to refinance $225 million of debt, a move that piled onto fresh concerns from a Bank of America downgrade and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results